Albireo Pharma Inc

NASDAQ:ALBO   3:59:54 PM EDT
26.80
-0.34 (-1.25%)
Products, Regulatory

Albireo Announces Positive Topline Data From Phase 1 Study Of A3907

Published: 12/16/2021 13:48 GMT
Albireo Pharma Inc (ALBO) - Albireo Announces Positive Topline Data From Phase 1 Study of A3907.
Albireo Pharma Inc - First Oral, Systemic Asbt Inhibitor Was Safe and Well Tolerated.
Albireo Pharma Inc - Secondary, Exploratory Objectives Show Favorable Pharmacokinetics, Systemic Exposure, While Providing Target Engagement Signals.
Albireo Pharma Inc - Company on Track to Initiate Planned Adult Liver Disease Phase 2 Study in 2022.
Albireo Pharma Inc - Study Achieved Both Primary and Secondary Objectives.